Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Biotech stocks returned up to 36% in 2025, while longevity investing hit $8.5B in funding. Here’s the data individual ...

Biotech firms are gaining major traction in 2026 due to the global pandemic. Take a look at some of the key features of ...

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice ...

Biotech stocks are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on ...

It’s hard to find a more experienced biotech investor than Evan McCulloch. The manager of Franklin Biotechnology Discovery has been running the $1.2 billion fund since 1997. That matters in this ...

Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it, the ...

The company's stock rose to a 52-week high of $9.35 on Wednesday. Last week, the company introduced the Fill-Tek Dispensing System for essential custom reagents, designed to ease bioprocessing ...

All that has changed, and if you want to invest in growth away from AI, biotech might be where you want to be. Below, I will attempt to lay out the various macro and policy disruptions that had a ...